| Literature DB >> 31627725 |
Yao Chen1, Yanyan Hu1, Jin Zhang1, Yue Shen2, Junling Huang1, Jun Yin1, Ping Wang1, Ying Fan1, Jianli Wang1, Su Lu1, Yilin Yang1, Lei Yan1, Keyong Li3, Zhenju Song4, Chaoyang Tong5, Shilin Du6.
Abstract
BACKGROUND: Secondary infection has a higher incidence in septic patients and affects clinical outcomes. This study aims to investigate the clinical characteristics, risk factors, immune status and prognosis of secondary infection of sepsis.Entities:
Keywords: Cytokine; HLA-DR; Immunosuppression; Secondary infection; Sepsis
Mesh:
Substances:
Year: 2019 PMID: 31627725 PMCID: PMC6800505 DOI: 10.1186/s12871-019-0849-9
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Study flowchart
Characteristics of septic patients classified according to developing secondary infection or not
| With secondary infection | Without secondary infection | ||
|---|---|---|---|
| Baseline characteristics | |||
| Age, median (25th,75th) | 66.5 (53.5–78.8) | 65 (52.3–75) | 0.323 |
| > 65 years, n (%) | 50 (54.3) | 105 (51.2) | 0.618 |
| Men, n (%) | 63 (68.5) | 132 (64.4) | 0.493 |
| Comorbidities, n (%) | |||
| None | 16 (17.4) | 40 (19.5) | 0.666 |
| Hypertension | 42 (45.7) | 82 (40) | 0.361 |
| Other cardiovascular diseasesa | 15 (16.3) | 25 (12.2) | 0.337 |
| Diabetes mellitus | 23 (25) | 46 (22.4) | 0.629 |
| Cerebrovascular diseases | 6 (6.5) | 13 (6.3) | 0.953 |
| Respiratory diseases | 9 (9.8) | 23 (11.2) | 0.712 |
| Hepatitis and cirrhosis | 3 (3.3) | 10 (4.9) | 0.761 |
| Renal insufficiency | 4 (4.3) | 15 (7.3) | 0.334 |
| Malignancy | 8 (8.7) | 17 (8.3) | 0.908 |
| Immunosuppression | 12 (13) | 24 (11.7) | 0.744 |
| Smoker, n (%) | 32 (34.8) | 69 (33.7) | 0.85 |
| Site of infection, n (%) | |||
| Respiratory tract | 70 (76.1) | 146 (71.2) | 0.384 |
| Abdomen | 15 (16.3) | 47 (22.9) | 0.194 |
| Urinary tract | 8 (8.7) | 14 (6.8) | 0.57 |
| Skin and soft tissue | 6 (6.5) | 6 (2.9) | 0.203 |
| Blood stream | 2 (2.2) | 2 (1) | 0.59 |
| More than one sites | 8 (8.7) | 13 (6.3) | 0.464 |
| In shock on admission, n (%) | 28 (30.4) | 49 (22.4) | 0.235 |
| Severity of disease, median (25th,75th) | |||
| APACHE II score | 17 (9.25–22) | 11 (7–18) | 0.001 |
| SOFA score | 4 (3–8) | 4 (2.5–6) | 0.007 |
| Monocyte HLA-DR expression (%)b | |||
| Day 1, mean (SD) | 31.6 (14.3) | 34.5 (14.9) | 0.364 |
| Day 3, median (25th,75th) | 28.6 (18.8–42) | 41.1 (27.5–50.4) | 0.048 |
| Day 7, median (25th,75th) | 29.6 (14.3–35.1) | 33.2 (13.8–65.4) | 0.722 |
| Levels of serum cytokines (pg/ml)b | |||
| Day 1, median (25th,75th) | |||
| IL-6 | 26.8 (13.6–363.5) | 21.1 (7.5–58.2) | 0.025 |
| IL-8 | 36.3 (18.7–70) | 22.9 (12–77.5) | 0.375 |
| IL-10 | 8.6 (5.4–24) | 10 (9.3–17.8) | 0.121 |
| Day 3, median (25th,75th) | |||
| IL-6 | 628.5 (23.5–1694.5) | 640.5 (17.8–942.3) | 0.478 |
| IL-8 | 29.89 (20–106) | 8 (4.9–15.6) | < 0.001 |
| IL-10 | 21.7 (6.4–35.3) | 14.6 (5–27.7) | 0.303 |
| Day 7 | |||
| IL-6, median (25th,75th) | 921 (652–1377) | 754 (584–1004) | 0.226 |
| IL-8, median (25th,75th) | 11.1 (6–41.8) | 12.5 (5.7–14) | 0.79 |
| IL-10, mean (SD) | 60.6 (47.3) | 16.8 (10.4) | 0.035 |
| Interventions, n (%)c | |||
| Glucocorticoid | 46 (50) | 80 (39) | 0.077 |
| Anticoagulation therapy | 33 (35.9) | 66 (32.2) | 0.535 |
| Mechanical ventilation | 68 (74) | 104 (50.7) | < 0.001 |
| Urinary catheterization | 72 (78.3) | 83 (40.5) | < 0.001 |
| Deep venous catheterization | 66 (71.7) | 74 (36.1) | < 0.001 |
| Continuous renal replacement therapy | 11 (12) | 19 (9.3) | 0.477 |
| Blood transfusion | 25 (27.2) | 30 (14.6) | 0.011 |
| LOS (days), median (25th,75th) | |||
| In-hospital | 23.5 (12–34) | 22 (10–32.5) | < 0.001 |
| ICU | 11 (7–17) | 11 (6–16.5) | < 0.001 |
| Mortality, n (%) | |||
| In-hospital | 42 (45.7) | 52 (25.4) | 0.001 |
| 30-day | 32 (34.8) | 48 (23.4) | 0.041 |
| 90-day | 39 (42.4) | 52 (25.4) | 0.003 |
aOther cardiovascular diseases included coronary heart disease, arrhythmia, myocardiosis and valvular heart disease
bData of 89, 77 and 21 patients were available for HLA-DR expression at day 1, 3 and 7 respectively, in which 35, 34 and 12 patients developed secondary infection. And data of 87, 38 and 18 patients were available for cytokines at day 1, 3 and 7 respectively, in which 33, 18 and 8 patients developed secondary infection
cIn the group of secondary infection, it referred to the interventions before the onset of secondary infection
Characteristics of secondary infections
| Site of infection, n (%) a | |
| Respiratory tract | |
| PNU | 83 (55.3) |
| LUNG | 1 (0.7) |
| Urinary tract | |
| SUTI | 41 (27.3) |
| OUTI | 1 (0.7) |
| Blood stream and disseminated infection | |
| LCBI | 12 (8) |
| DI | 6 (4) |
| Abdomen | |
| IAB | 4 (2.7) |
| GIT | 1 (0.7) |
| Skin and soft tissue | |
| ST | 1 (0.7) |
| Time of onset of the first identified secondary infection | |
| Median (25th,75th) | 8 (5.25,14) |
| Time range, n (%) | |
| day 3 | 5 (5.4) |
| > day 3, ≤day 7 | 36 (39) |
| > day 7, ≤day 15 | 33 (35.9) |
| > day 15 | 18 (19.6) |
| Patients with multiple secondary infections, n (%) | 26 (28.3) |
| Secondary infection without identified pathogens, n (%) | 23 (15.3) |
aDiagnosis was according to CDC/NHSN criteria [25]. PNU Pneumonia, LUNG Other infections of the lower respiratory tract, SUTI Symptomatic urinary tract infection, OUTI Other infections of the urinary tract, DI Disseminated infection, GIT Gastrointestinal tract, IAB Intraabdominal infection, LCBI Laboratory-confirmed bloodstream infection, ST Soft tissue infection
Results of multivariate logistic regression test of the risk factors of secondary infection
| Variablesa | Partial regression coefficient | Standard error | Wald χ2 | OR | 95% CI | |
|---|---|---|---|---|---|---|
| Urinary catheterization | 1.219 | 0.325 | 14.109 | < 0.001 | 3.384 | 1.791–6.392 |
| Deep venous catheterization | 0.959 | 0.309 | 9.601 | 0.002 | 2.608 | 1.422–4.784 |
aAnalysis was conducted by method Backward: Conditional. Variable blood transfusion was removed on step 2, mechanical ventilation on step 3, APACHE II score on step 4 and SOFA score on step 5
Fig. 2Biomarkers of immune status in septic patients stratified according to developing secondary infection or not. Data of a part of patients were available for HLA-DR expression and cytokines and the exact numbers were shown in Table 1. Data were presented as medians (shown as triangles or circles) and 25- and 75- percentile error bars. Exceptions were mean and standard deviation error bars were used in HLA-DR expression at day 1 and IL-10 level at day 7. a and b represented the levels and dynamic changes of two anti-inflammatory biomarkers (HLA-DR and IL-10) respectively. c and d represented the levels and dynamic changes of two pro-inflammatory biomarkers (IL-6 and IL-8) respectively. * P < 0.05, ** P < 0.01, *** P < 0.001. SI, secondary infection; NSI, non-secondary infection
Fig. 3Representative plots of monocyte HLA-DR measurement by flow cytometry. Monocyte HLA-DR expression was measured by flow cytometry. The samples were collected at day 3 after admission. a The left dot-plot (SSC vs. FITC) delimited the monocytic region. The right dot-plot (APC vs. FITC) delimited the CD14+ HLA-DR+ monocyte (upper right region). The analysis was performed on a patient with immunosuppression as was reflected by the decreased proportion of CD14+ HLA-DR+ monocyte (18.5%). b The same strategy of analysis was used on a patient without immunosuppression. FITC, fluorescein isothiocyanate; APC, allophycocyanin; SSC, side scatter
Fig. 4Expected length of stay of septic patients with and without secondary infection. SI, secondary infection; NSI, non-secondary infection
Fig. 5Kaplan-Meier survival curves of overall septic patients before day 90. SI, secondary infection; NSI, non-secondary infection